Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2022-06-22 Director's Dealing
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Issue of Warrants
Director's Dealing Classification · 99% confidence The document is an RNS announcement from Roquefort Therapeutics PLC dated June 22, 2022. The primary content details the 'Issue of Warrants' to newly appointed Non-Executive Directors and an advisor as part of their remuneration. Crucially, the document concludes with detailed tables titled 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' (MAR disclosures). These disclosures relate to transactions (issuance of warrants) by persons discharging managerial responsibilities (PDMRs). This specific reporting requirement—disclosure of insider transactions—is typically covered under regulations like MAR, which mandates reporting of director/insider dealings. While the warrants are part of remuneration (which might suggest DEF 14A), the core regulatory filing structure here is the mandatory disclosure of transactions by directors. This aligns most closely with the 'Director's Dealing' category (DIRS), which covers personal share transactions by directors and executives, even if the instrument is warrants rather than shares. Since it is a mandatory regulatory disclosure about insider transactions, DIRS is the most specific fit over the general RNS fallback.
2022-06-22 English
Investor Presentation
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4187 characters) released via RNS, identified by the RNS Number '7983P'. The key content is the announcement that the company will provide a live presentation to discuss the 'Proposed Acquisition of Oncogeni and Proposed Placing' via the 'Investor Meet Company platform'. The document explicitly states it is an 'Investor Presentation' announcement and provides details on how to attend the event. This fits the definition of an Investor Presentation (IP) being announced, rather than the presentation material itself. Since it is an announcement about an upcoming investor event/presentation, 'IP' is the most specific fit. If the document were the actual presentation slides or detailed script, 'IP' would still apply, but given the context of an RNS announcement detailing *when* and *where* the presentation will occur, it functions as an announcement of that event.
2022-06-22 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1938 characters) and its primary content is an announcement regarding a 'Second Price Monitoring Extension' for a security, referencing the RNS Number and the London Stock Exchange. It explicitly states that this information is provided by RNS, the news service of the London Stock Exchange, and is approved by the FCA as a Primary Information Provider. This type of immediate, brief regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or IR) is best classified as a general Regulatory Filing or announcement, which corresponds to the RNS code.
2022-06-22 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1921 characters) and contains an RNS Number, a date, and a brief announcement titled 'Price Monitoring Extension'. It describes an extension of the auction call period for a security, which is a specific operational notice related to trading on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the FCA as a Primary Information Provider. Since this is a specific, non-standard regulatory announcement that doesn't fit into the defined categories like ER, 10-K, or DIV, and it is a direct regulatory notification, the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings).
2022-06-22 English
Proposed Acquisition of Oncogeni Limited & Placing
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from Roquefort Therapeutics plc, dated June 22, 2022. The content details a 'Proposed Acquisition of Oncogeni Limited' and a 'Proposed Placing of 7,249,998 Ordinary Shares'. This announcement describes a significant corporate transaction (M&A and fundraising) and is clearly structured as a regulatory disclosure, indicated by the 'RNS Number' header and the disclaimer regarding 'inside information' and 'Market Abuse Regulation'. Since the document describes a major corporate action (acquisition and placing) rather than being a standard periodic financial report (like 10-K or IR) or a simple announcement of a report's publication (RPA), it fits best under the general 'Regulatory Filings' category (RNS) as it is a material, non-standard corporate event disclosure made via the Regulatory Information Service. It is not specifically a Director's Dealing (DIRS), Capital/Financing Update (CAP) which usually focuses only on the financing aspect, or M&A Activity (TAR) which is usually for takeover bids, making RNS the most appropriate general regulatory disclosure code for this type of material event announcement.
2022-06-22 English
Notice of AGM - Correction
AGM Information Classification · 98% confidence The document is titled "Notice of Annual General Meeting - Correction". It explicitly refers to the previous announcement giving notice of the Annual General Meeting (AGM) and corrects a typographical error within the Notice document itself. Since this is an announcement correcting details related to the AGM materials (Notice of Resolutions), it directly relates to the AGM process. The most specific category is AGM Information (AGM-R). Although it is a correction announcement, the core subject matter is the AGM itself, making AGM-R more appropriate than the general RPA or RNS, as AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. Given the content is a correction to the AGM Notice, AGM-R is the best fit.
2022-06-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.